Adult Growth Hormone Deficiency
Aug 01, 2025
Overcoming Adherence Challenges in Growth Hormone Deficiency Treatment: The Promise of Long-Acting and Oral Therapies
Growth hormone deficiency (GHD) is a rare condition that arises from inadequate secretion of growth hormone by the anterior pituitary gland. It can originate from birth (congenital), develop later in life (acquired), or occur without a known cause (idiopathic), underscoring the complex mix of genetic, environmental...
Read More...
Jul 29, 2025
Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency; Apellis Wins FDA Approval for EMPAVELI in C3G and IC-MPGN Treatment; FDA Approves PTC Therapeutics’ Sephience for Phenylketonuria; MAIA Biotechnology’s Ateganosine Gets FDA Fast Track for Non-Small Cell Lung Cancer; Entera Bio Gets FDA Nod on BMD as Primary Endpoint for Phase III Osteoporosis Study
Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency Ascendis Pharma A/S announced that the FDA has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). Already approved for pediatric GHD since 2021, SKYTROFA is a once-weekly prodrug of ...
Read More...
Feb 21, 2024
Hormone Replacement Therapy Market: Unveiling the Growth Opportunities and Key Players Exploring the Domain
Hormone Replacement Therapy (HRT) stands as a big ray of hope for individuals affected by the multifaceted challenges of hormonal imbalances. Defined as the administration of synthetic or natural hormones to supplement or replace the body's own hormonal levels, Hormone Replacement Therapy has emerged as a cornersto...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
